Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin versus Investigators Choice (IC) for relapsed/refractory b-cell acute lymphoblastic leukaemia (R/R B-ALL)
Authors:
Batteson R, Critchlow S, Barnes A, Glah D, Smith A, Lang K and Su Y.
Publication type:
Poster PCN205
Conference name:
20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress
Citation:
Batteson R, Critchlow S, Barnes A, Glah D, Smith A, Lang K and Su Y. Quality-Adjusted Life Years (QALYS) for Inotuzumab Ozogamicin versus Investigators Choice (IC) for relapsed/refractory b-cell acute lymphoblastic leukaemia (R/R B-ALL). 20th International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Annual European Congress. Glasgow: Scotland, 2017.
